Éverton de Almeida Alves Barbosa

Éverton de Almeida Alves Barbosa

Auto-generated profile, based on publicly available information

Éverton de Almeida Alves Barbosa

Universidade Federal de Viçosa, Departamento de Bioquímica e Biologia Molecular, Viçosa, MG, Brazil

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 August 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RSRaoni Pais Siqueira
Raoni Pais Siqueira
ÉBÉverton de Almeida Alves Barbosa
Éverton de Almeida Alves Barbosa
MPMarcelo Depólo Polêto
Marcelo Depólo Polêto
GRGermanna Lima Righetto
Germanna Lima Righetto
TSThiago Vargas Seraphim
Thiago Vargas Seraphim
GBGustavo Costa Bressan
Gustavo Costa Bressan
Dysregulation of pre-mRNA splicing machinery activity has been related to the biogenesis of several diseases. The serine/arginine-rich protein kinase family (SRPKs) plays a critical role in regulating pre-mRNA splicing events through the extensive phosphorylation of splicing factors from the family of serine/arginine-rich proteins (SR proteins). Previous investigations have described the overexpression of SRPK1 and SRPK2 in leukemia and other cancer types, suggesting that they would be useful targets for developing novel antitumor strategies. Herein, we evaluated the effect of selective pharmacological SRPK inhibition by N-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl)isonicotinamide (SRPIN340) on the viability of lymphoid and myeloid leukemia cell lines. Along with significant cytotoxic activity, the effect of treatments in regulating the phosphorylation of the SR protein family and in altering the expression of MAP2K1, MAP2K2, VEGF and FAS genes were also assessed. Furthermore, we found that pharmacological inhibition of SRPKs can trigger early and late events of apoptosis. Finally, intrinsic tryptophan fluorescence emission, molecular docking and molecular dynamics were analyzed to gain structural information on the SRPK/SRPIN340 complex. These data suggest that SRPK pharmacological inhibition should be considered as an alternative therapeutic strategy for fighting leukemias. Moreover, the obtained SRPK-ligand interaction data provide useful structural information to guide further medicinal chemistry efforts towards the development of novel drug candidates.

1 October 2020 in Colloids and Surfaces A: Physicochemical and Engineering Aspects
Verified
Journal Article
Closed access
AOAna Paula Hanke de Oliveira
Ana Paula Hanke de Oliveira
MOMichele Harumi Omura
Michele Harumi Omura
ÉBÉverton de Almeida Alves Barbosa
Éverton de Almeida Alves Barbosa
GBGustavo Costa Bressan
Gustavo Costa Bressan
ÉVÉrica Nascif Rufino Vieira
Érica Nascif Rufino Vieira
EOEduardo Basílio De Oliveira
Eduardo Basílio De Oliveira

1 January 2015 in BioMed Research International
Verified
Journal Article
Open access
PDF file
MSMaria Roméria da Silva
Maria Roméria da Silva
GMGabriela Alves Moreira
Gabriela Alves Moreira
RSRonni Anderson Gonçalves da Silva
Ronni Anderson Gonçalves da Silva
ÉBÉverton de Almeida Alves Barbosa
Éverton de Almeida Alves Barbosa
RSRaoni Pais Siqueira
Raoni Pais Siqueira
GBGustavo Costa Bressan
Gustavo Costa Bressan
Alternative splicing allows cells to expand the encoding potential of their genomes. In this elegant mechanism, a single gene can yield protein isoforms with even antagonistic functions depending on the cellular physiological context. Alterations in splicing regulatory factors activity in cancer cells, however, can generate an abnormal protein expression pattern that promotes growth, survival, and other processes, which are relevant to tumor biology. In this review, we discuss dysregulated alternative splicing events and regulatory factors that impact pathways related to cancer. The SR proteins and their regulatory kinases SRPKs and CLKs have been frequently found altered in tumors and are examined in more detail. Finally, perspectives that support splicing machinery as target for the development of novel anticancer therapies are discussed.

1 July 2017 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
RSRaoni Pais Siqueira
Raoni Pais Siqueira
MBMarcus Vinícius de Andrade Barros
Marcus Vinícius de Andrade Barros
ÉBÉverton de Almeida Alves Barbosa
Éverton de Almeida Alves Barbosa
TOThiago Souza Onofre
Thiago Souza Onofre
VGVictor Hugo Sousa Gonçalves
Victor Hugo Sousa Gonçalves
GBGustavo Costa Bressan
Gustavo Costa Bressan

1 October 2018 in Toxicology and Applied Pharmacology
Verified
Journal Article
Closed access
GMGabriela Alves Moreira
Gabriela Alves Moreira
GLGraziela Domingues de Almeida Lima
Graziela Domingues de Almeida Lima
RSRaoni Pais Siqueira
Raoni Pais Siqueira
MBMarcus Vinícius de Andrade Barros
Marcus Vinícius de Andrade Barros
AAAbraham Landry Mahuvi Adjanohoun
Abraham Landry Mahuvi Adjanohoun
GBGustavo Costa Bressan
Gustavo Costa Bressan

1 October 2017 in Food Research International
Verified
Journal Article
Closed access
CSCamila Santiago Saraiva
Camila Santiago Saraiva
JCJane SELIA DOS REIS Coimbra
Jane SELIA DOS REIS Coimbra
ATAlvaro Vianna Novaes de Carvalho Teixeira
Alvaro Vianna Novaes de Carvalho Teixeira
EOEduardo Basílio De Oliveira
Eduardo Basílio De Oliveira
RTReinaldo Francisco Teófílo
Reinaldo Francisco Teófílo
ÉBÉverton de Almeida Alves Barbosa
Éverton de Almeida Alves Barbosa